A Core Glycolipid Vaccine Elicits Cross-reactive Antibodies Against <i>Salmonella</i> Species and Protects Against Invasive Nontyphoidal <i>Salmonella</i> Disease in Mice
Our findings support the development of core glycolipids as a novel Salmonella vaccine candidate. Further investigation is warranted to determine the efficacy of the J5 core/outer membrane protein vaccine against other Salmonella serovars of concern.
Authors
- Alan S. Cross (ORCID: https://orcid.org/0000-0003-4362-9936)
- Surekha Shridhar (ORCID: https://orcid.org/0000-0003-1820-7379)
- Jacqueline Kolasny (ORCID: https://orcid.org/0000-0002-1751-0600)
- Sang Hyun (ORCID: https://orcid.org/0000-0001-8426-3331)
- Sharon M. Tennant (ORCID: https://orcid.org/0000-0002-0651-5748)
- Scott M. Baliban (ORCID: https://orcid.org/0000-0002-2771-1609)
- Zhiyong Zhao (ORCID: https://orcid.org/0000-0002-6145-7464)
- Kun Luo (ORCID: https://orcid.org/0000-0003-2255-2749)
Institutions
- University of Maryland, Baltimore (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1093/infdis/jiae641
- Citations
- 2
- Primary Topic
- Salmonella and Campylobacter epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- National Institute of Allergy and Infectious Diseases